Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05153330
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:37.454695+00:00
Published At
2025-07-03T00:00:00+00:00
Record Updated At
2025-07-03
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Acute Mixed-Phenotype Leukemia", "Cancer", "Refractory", "Progression", "Diffuse Large B Cell Lymphoma", "Multiple Myeloma", "Lymphoma", "Lymphoma, Non-Hodgkin", "Myeloma, Plasma-Cell", "Myelomatosis", "Plasma Cell Myeloma", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-07-03"
protocolSection.identificationModule.nctId
"NCT05153330"
protocolSection.identificationModule.officialTitle
"A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Acute Mixed-Phenotype Leukemia (protocolSection.conditionsModule.conditions)
  • Cancer (protocolSection.conditionsModule.conditions)
  • Refractory (protocolSection.conditionsModule.conditions)
  • Progression (protocolSection.conditionsModule.conditions)
  • Diffuse Large B Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Multiple Myeloma (protocolSection.conditionsModule.conditions)
  • Lymphoma (protocolSection.conditionsModule.conditions)
  • Lymphoma, Non-Hodgkin (protocolSection.conditionsModule.conditions)
  • Myeloma, Plasma-Cell (protocolSection.conditionsModule.conditions)
  • Myelomatosis (protocolSection.conditionsModule.conditions)
  • Plasma Cell Myeloma (protocolSection.conditionsModule.conditions)
  • Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.